Soluble CD30 correlates with clinical but not subclinical renal allograft rejection

Transplant International

Volumn 26, Issue 1, 2013, Pages 75-83

  Hirt Minkowski, Patricia ^a   Roth, Michèle ^a   Hönger, Gideon ^a   Amico, Patrizia ^a   Hopfer, Helmut ^b   Schaub, Stefan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

allograft rejection; noninvasive monitoring; soluble CD30

Indexed keywords

CD30 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIGENS, CD30; BIOPSY; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871259486     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01578.x     Document Type: Article

References (40)

1. El-Zoghby ZM, Stegall MD, Lager DJ, etal. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
2. Susal C, Opelz G,. Options for immunologic support of renal transplantation through the HLA and immunology laboratories. Am J Transplant 2007; 7: 1450.
3. Mengel M, Chapman JR, Cosio FG, etal. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am J Transplant 2007; 7: 512.
4. Heilman RL, Devarapalli Y, Chakkera HA, etal. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10: 563.
5. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242.
6. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD,. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987.
7. Henderson LK, Nankivell BJ, Chapman JR,. Surveillance protocol kidney transplant biopsies: their evolving role in clinical practice. Am J Transplant 2011; 11: 1570.
8. Del PG, De CM, D'Elios MM, etal. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 1995; 182: 1655.
9. Romagnani S, Parronchi P, D'Elios MM, etal. An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 1997; 113: 153.
10. Pelzl S, Opelz G, Wiesel M, etal. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002; 73: 3.
11. Susal C, Pelzl S, Dohler B, Opelz G,. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650.
12. Cinti P, Pretagostini R, Arpino A, etal. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 2005; 79: 1154.
13. Vaidya S, Partlow D, Barnes T, Thomas P, Gugliuzza K,. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies. Clin Transplant 2006; 20: 461.
14. Rodriguez LM, Paris SC, Arbelaez M, etal. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 2007; 68: 652.
15. Heinemann FM, Rebmann V, Witzke O, Philipp T, Broelsch CE, Grosse-Wilde H,. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 2007; 83: 706.
16. Iv R, He Q, Wang HP, Jin J, Chen Y, Chen JH,. High serum level of the soluble CD30 identifies Chinese kidney transplant recipients at high risk of unfavorable outcome. Transplant Proc 2008; 40: 3375.
17. Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B,. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 2006; 81: 1216.
18. Wang D, Wu GJ, Wu WZ, etal. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol 2007; 17: 278.
19. Yang JL, Hao HJ, Zhang B, Liu YX, Chen S, Na YQ,. Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes. Transplant Proc 2008; 40: 3381.
20. Pelzl S, Opelz G, Daniel V, Wiesel M, Susal C,. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003; 75: 421.
21. Dong W, Shunliang Y, Weizhen W, etal. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 2006; 16: 41.
22. Matinlauri IH, Kyllonen LE, Salmela KT, Helin H, Pelzl S, Susal C,. Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations. Transplantation 2005; 80: 1809.
23. Ayed K, Abdallah TB, Bardi R, Abderrahim E, Kheder A,. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection. Transplant Proc 2006; 38: 2300.
24. Cervelli C, Fontecchio G, Scimitarra M, etal. Evaluation of serum sCD30 in renal transplantation patients with and without acute rejection. Transplant Proc 2009; 41: 1159.
25. Nafar M, Farrokhi F, Vaezi M, etal. Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection. Int Urol Nephrol 2009; 41: 687.
26. Kamali K, Abbasi MA, Farokhi B, etal. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection. Exp Clin Transplant 2009; 7: 237.
27. Slavcev A, Lacha J, Honsova E, etal. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 2005; 14: 117.
28. Susal C, Dohler B, Sadeghi M, etal. Posttransplant sCD30 as a predictor of kidney graft outcome. Transplantation 2011; 91: 1364.
29. Kim MS, Kim HJ, Kim SI, etal. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation. Transplantation 2006; 82: 1602.
30. Platt RE, Wu KS, Poole K, Newstead CG, Clark B,. Soluble CD30 as a prognostic factor for outcome following renal transplantation. J Clin Pathol 2009; 62: 662.
31. Kovac J, Arnol M, Vidan JB, Bren AF, Kandus A,. Pretransplant soluble CD30 serum concentration does not affect kidney graft outcomes 3 years after transplantation. Transplant Proc 2010; 42: 4043.
32. Halim MA, Al-Otaibi T, Al-Muzairai I, etal. Serial soluble CD30 measurements as a predictor of kidney graft outcome. Transplant Proc 2010; 42: 801.
33. Amico P, Hirt-Minkowski P, Honger G, etal. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Transpl Int 2011; 24: 560.
34. Sis B, Mengel M, Haas M, etal. Banff -̃09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups. Am J Transplant 2010; 10: 464.
35. Grimm PC, McKenna R, Nickerson P, etal. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 1999; 10: 1582.
36. Schaub S, Nickerson P, Rush D, etal. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009; 9: 1347.
37. Ho J, Rush DN, Karpinski M, etal. Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. Transplantation 2011; 92: 878.
38. Romagnani S, Del PG, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G,. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995; 57: 726.
39. Weimer R, Susal C, Yildiz S, etal. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006; 6: 1865.
40. Domingues EM, Matuck T, Graciano ML, etal. Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant. Clin Transplant 2010; 24: 821.